Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Anders Soehoel, Malte Selch Larsen, Stine Timmermann, Anders Soehoel, Malte Selch Larsen, Stine Timmermann
Abstract
Tralokinumab is the first biologic therapy for moderate-to-severe atopic dermatitis (AD) that specifically neutralizes interleukin-13 activity, a key driver of AD signs and symptoms. Tralokinumab is a human immunoglobulin G4 monoclonal antibody administered subcutaneously every 2 weeks (with possibility of maintenance dosing every 4 weeks). This population pharmacokinetic (PK) analysis aimed to identify sources of PK variability and relevant predictors of tralokinumab exposure in adults with moderate to severe AD. Nonlinear mixed-effect modeling, including covariate analysis, was used on a data set including 2561 subjects (AD, asthma, healthy) from 10 clinical trials. A 2-compartment model with first-order absorption and elimination adequately described the tralokinumab PK. Body weight was identified as a relevant predictor of tralokinumab exposure; other covariates including age, sex, race, ethnicity, disease type, AD severity, and renal and hepatic impairment were not. For body weight, the difference in exposure between the upper- and lower-weight quartiles in patients with AD was <2-fold, supporting the appropriateness of flat dosing (300 mg). Given the reduced exposure associated with higher body weight, coupled with the reduced exposure provided by dosing every 4 weeks, it is uncertain whether higher-weight patients will achieve sufficient exposure to maintain efficacy if dosed every 4 weeks instead of the standard every 2 weeks.
Trial registration: ClinicalTrials.gov NCT03526861.
Keywords: IL-13; atopic dermatitis; population pharmacokinetics; tralokinumab.
Conflict of interest statement
The authors declare no conflicts of interest.
© 2022 LEO Pharma A/S. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Figures
References
- Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1‐20.
- Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284‐1293.
- Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population‐based cross‐sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340‐347.
- Bieber T. Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54‐62.
- Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co‐opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217‐228.e213.
- Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003; 171(6):3262‐3269.
- Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL‐13‐dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480‐1489.
- Szegedi K, Lutter R, Res PC, et al. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015;29(11):2136‐2144.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116‐132.
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657‐682.
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850‐878.
- Blanchard C, Mishra A, Saito‐Akei H, Monk P, Anderson I, and Rothenberg ME. Inhibition of human interleukin‐13‐induced respiratory and oesophageal inflammation by anti‐human‐interleukin‐13 antibody (CAT‐354). Clin Exp Allergy. 2005;35(8):1096‐1103.
- May RD, Monk PD, Cohen ES, et al. Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 2012;166(1):177‐193.
- Thom G, Minter R. Optimization of CAT‐354, a therapeutic antibody directed against interleukin‐13, using ribosome display. Methods Mol Biol. 2012;805:393‐401.
- Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL‐13‐neutralising monoclonal antibody tralokinumab as inhibition of binding to IL‐13Rα1 and IL‐13Rα2. J Mol Biol. 2017;429(2):208‐219.
- Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437‐449.
- Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450‐463.
- Tollenaere MAX, Litman T, Moebus L, et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin‐13 and modulated by tralokinumab in vitro. Acta Derm Venereol. 2021;101(4):adv00447.
- Baverel PG, Jain M, Stelmach I, et al. Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. Br J Clin Pharmacol. 2015;80(6):1337‐1349.
- Oh CK, Faggioni R, Jin F, et al. An open‐label, single‐dose bioavailability study of the pharmacokinetics of CAT‐354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol. 2010;69(6):645‐655.
- Bajaj G, Suryawanshi S, Roy A, and Gupta M. Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. Br J Clin Pharmacol. 2019;85(9):2045‐2058.
- Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633‐659.
- Tunblad K, Lindbom L, McFadyen L, Jonsson EN, Marshall S, Karlsson MO. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn. 2008;35(5): 503‐526.
- Karlsson MO, Holford N: A tutorial on visual predictive checks. Abstract 1434, p. 17. Presented at: Annual Meeting of the Population Approach Group in Europe; June 18–20, 2008; Marseille, France.
- Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies–mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007;10(1):84‐96.
- Davda JP, Dodds MG, Gibbs MA, Wisdom W, Gibbs J. A model‐based meta‐analysis of monoclonal antibody pharmacokinetics to guide optimal first‐in‐human study design. MAbs. 2014;6(4):1094‐1102.
- Garg A, Quartino A, Li J, et al. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2‐targeted monoclonal antibody, and evaluation of a fixed, non‐weight‐based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol. 2014;74(4):819‐829.
- Singh SK. Impact of product‐related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354‐387.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1‐266.
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604‐612.
- Mansfield AS, Rudek MA, Vulih D, Smith GL, Harris PJ, Ivy SP, Group NCIODW . The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects. Clin Cancer Res. 2016;22(22):5472‐5479.
Source: PubMed